We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 14, 2021

[18F]-FDG PET/CT for Assessing Early Metabolic Response in HR+/HER2− MBC Treated With CDK4/6 Inhibitors

Oncology Research and Treatment


Additional Info

Oncology Research and Treatment
[18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients With Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated With Cyclin-Dependent 4/6 Kinase Inhibitors
Oncol Res Treat 2021 Jun 08;[EPub Ahead of Print], R Seifert, A Küper, M Tewes, M Heuschmid, A Welt, WP Fendler, K Herrmann, T Decker

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading